Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2025-03-18 Sale |
2025-03-20 4:34 pm |
CytomX Therapeutics Inc. | CTMX | McCarthy Sean A. CEO |
37,656 | $0.599 | $22,556 | 1,088,353 (Indirect Direct) |
View |
| 2025-03-18 Sale |
2025-03-20 4:33 pm |
CytomX Therapeutics Inc. | CTMX | Ogden Christopher Chief Financial Officer |
8,551 | $0.599 | $5,122 | 201,026 (Direct) |
View |
| 2025-03-18 Sale |
2025-03-20 4:32 pm |
CytomX Therapeutics Inc. | CTMX | Chu Yu-Waye Chief Medical Officer |
4,025 | $0.599 | $2,411 | 135,725 (Direct) |
View |
| 2025-03-18 Sale |
2025-03-20 4:32 pm |
CytomX Therapeutics Inc. | CTMX | ROWLAND LLOYD A General Counsel |
10,203 | $0.599 | $6,112 | 120,594 (Direct) |
View |
| 2025-03-18 Sale |
2025-03-20 4:31 pm |
CytomX Therapeutics Inc. | CTMX | BELVIN MARCIA SVP, Chief Scientific Officer |
19,512 | $0.599 | $11,688 | 248,636 (Direct) |
View |
| 2024-08-20 Sale |
2024-08-22 6:01 pm |
CytomX Therapeutics Inc. | CTMX | Landau Jeffrey B Chief Business Officer |
4,181 | $1.2291 | $5,139 | 126,736 (Indirect Direct) |
View |
| 2024-08-20 Sale |
2024-08-22 6:01 pm |
CytomX Therapeutics Inc. | CTMX | BELVIN MARCIA SVP, Chief Scientific Officer |
4,181 | $1.2291 | $5,139 | 175,648 (Direct) |
View |
| 2024-08-20 Sale |
2024-08-22 6:00 pm |
CytomX Therapeutics Inc. | CTMX | ROWLAND LLOYD A General Counsel |
4,181 | $1.2291 | $5,139 | 130,797 (Direct) |
View |
| 2024-08-20 Sale |
2024-08-22 5:59 pm |
CytomX Therapeutics Inc. | CTMX | Ogden Christopher Chief Financial Officer |
1,984 | $1.2291 | $2,439 | 108,077 (Direct) |
View |
| 2024-08-20 Sale |
2024-08-22 5:58 pm |
CytomX Therapeutics Inc. | CTMX | McCarthy Sean A. CEO |
13,898 | $1.2291 | $17,082 | 751,009 (Indirect Direct) |
View |
| 2024-03-19 Sale |
2024-03-21 4:41 pm |
CytomX Therapeutics Inc. | CTMX | ROWLAND LLOYD A General Counsel |
5,268 | $2.0855 | $10,986 | 117,728 (Direct) |
View |
| 2024-03-19 Sale |
2024-03-21 4:40 pm |
CytomX Therapeutics Inc. | CTMX | McCarthy Sean A. CEO |
20,223 | $2.0855 | $42,175 | 617,639 (Indirect Direct) |
View |
| 2024-03-19 Sale |
2024-03-21 4:38 pm |
CytomX Therapeutics Inc. | CTMX | Ogden Christopher SVP, Finance and Accounting |
2,971 | $2.0855 | $6,196 | 85,686 (Direct) |
View |
| 2024-03-19 Sale |
2024-03-21 4:37 pm |
CytomX Therapeutics Inc. | CTMX | BELVIN MARCIA SVP, Chief Scientific Officer |
12,795 | $2.0855 | $26,684 | 168,579 (Direct) |
View |
| 2024-03-19 Sale |
2024-03-21 4:36 pm |
CytomX Therapeutics Inc. | CTMX | Landau Jeffrey B Chief Business Officer |
6,562 | $2.0855 | $13,685 | 117,740 (Indirect Direct) |
View |
| 2023-12-20 Sale |
2023-12-22 4:16 pm |
CytomX Therapeutics Inc. | CTMX | McCarthy Sean A. CEO |
13,551 | $1.3807 | $18,710 | 547,862 (Indirect Direct) |
View |
| 2023-12-20 Sale |
2023-12-22 4:14 pm |
CytomX Therapeutics Inc. | CTMX | BELVIN MARCIA SVP, Chief Scientific Officer |
4,077 | $1.3805 | $5,628 | 155,124 (Direct) |
View |
| 2023-12-20 Sale |
2023-12-22 4:12 pm |
CytomX Therapeutics Inc. | CTMX | Landau Jeffrey B Chief Business Officer |
4,077 | $1.3805 | $5,628 | 94,302 (Indirect Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2025-02-04 Option Award(A) |
2025-02-10 5:58 pm |
N/A 2035-02-03 |
CytomX Therapeutics Inc. | CTMX | BELVIN MARCIA SVP, Chief Scientific Officer |
357,500 | $0 | 533,148 (Direct) |
View |
| 2025-02-04 Option Award |
2025-02-06 5:57 pm |
N/A 2035-02-03 |
CytomX Therapeutics Inc. | CTMX | BELVIN MARCIA SVP, Chief Scientific Officer |
342,500 | $0 | 518,148 (Direct) |
View |
| 2025-02-04 Option Award |
2025-02-06 5:55 pm |
N/A 2035-02-03 |
CytomX Therapeutics Inc. | CTMX | Chu Yu-Waye Chief Medical Officer |
466,500 | $0 | 492,750 (Direct) |
View |
| 2025-02-04 Option Award |
2025-02-06 5:55 pm |
N/A 2035-02-03 |
CytomX Therapeutics Inc. | CTMX | Ogden Christopher Chief Financial Officer |
441,500 | $0 | 549,577 (Direct) |
View |
| 2025-02-04 Option Award |
2025-02-06 5:54 pm |
N/A 2035-02-03 |
CytomX Therapeutics Inc. | CTMX | McCarthy Sean A. CEO |
1,565,000 | $0 | 2,316,009 (Direct) |
View |
| 2024-08-20 Exercise |
2024-08-22 6:01 pm |
N/A N/A |
CytomX Therapeutics Inc. | CTMX | Landau Jeffrey B Chief Business Officer |
11,250 | $0 | 126,736 (Direct) |
View |
| 2024-08-20 Exercise |
2024-08-22 6:01 pm |
N/A N/A |
CytomX Therapeutics Inc. | CTMX | BELVIN MARCIA SVP, Chief Scientific Officer |
11,250 | $0 | 175,648 (Direct) |
View |
| 2024-08-20 Exercise |
2024-08-22 6:00 pm |
N/A N/A |
CytomX Therapeutics Inc. | CTMX | ROWLAND LLOYD A General Counsel |
11,250 | $0 | 130,797 (Direct) |
View |
| 2024-08-20 Exercise |
2024-08-22 5:59 pm |
N/A N/A |
CytomX Therapeutics Inc. | CTMX | Ogden Christopher Chief Financial Officer |
6,875 | $0 | 108,077 (Direct) |
View |
| 2024-08-20 Exercise |
2024-08-22 5:58 pm |
N/A N/A |
CytomX Therapeutics Inc. | CTMX | McCarthy Sean A. CEO |
37,500 | $0 | 751,009 (Direct) |
View |
| 2024-06-12 Option Award |
2024-06-14 4:24 pm |
N/A 2034-06-11 |
CytomX Therapeutics Inc. | CTMX | Ogden Christopher Chief Financial Officer |
92,500 | $0 | 178,186 (Direct) |
View |
| 2024-05-15 Option Award |
2024-05-17 5:36 pm |
N/A 2034-05-14 |
CytomX Therapeutics Inc. | CTMX | Young Matthew P. Director |
38,000 | $0 | 38,000 (Direct) |
View |
| 2024-05-15 Option Award |
2024-05-17 5:36 pm |
N/A 2034-05-14 |
CytomX Therapeutics Inc. | CTMX | Su Zhen Director |
38,000 | $0 | 38,000 (Direct) |
View |
| 2024-05-15 Option Award |
2024-05-17 5:34 pm |
N/A 2034-05-14 |
CytomX Therapeutics Inc. | CTMX | Mohindru Mani Director |
38,000 | $0 | 38,000 (Direct) |
View |
| 2024-05-15 Option Award |
2024-05-17 5:34 pm |
N/A 2034-05-14 |
CytomX Therapeutics Inc. | CTMX | Meyers James R Director |
38,000 | $0 | 38,000 (Direct) |
View |
| 2024-05-15 Option Award |
2024-05-17 5:33 pm |
N/A 2034-05-14 |
CytomX Therapeutics Inc. | CTMX | Jones Elaine V Director |
38,000 | $0 | 38,000 (Direct) |
View |
| 2024-05-15 Option Award |
2024-05-17 5:32 pm |
N/A 2034-05-14 |
CytomX Therapeutics Inc. | CTMX | Gilbert Halley E Director |
38,000 | $0 | 38,000 (Direct) |
View |
| 2024-05-15 Option Award |
2024-05-17 5:31 pm |
N/A 2034-05-14 |
CytomX Therapeutics Inc. | CTMX | Ashworth Alan Director |
38,000 | $0 | 38,000 (Direct) |
View |
| 2024-03-26 Exercise |
2024-03-28 7:12 pm |
N/A N/A |
CytomX Therapeutics Inc. | CTMX | McCarthy Sean A. CEO |
109,768 | $1.5749 | 727,407 (Direct) |
View |
| 2024-03-26 Exercise |
2024-03-28 7:12 pm |
N/A 2025-02-08 |
CytomX Therapeutics Inc. | CTMX | McCarthy Sean A. CEO |
109,768 | $0 | 727,407 (Direct) |
View |
| 2024-03-20 Option Award |
2024-03-22 4:27 pm |
N/A 2034-03-19 |
CytomX Therapeutics Inc. | CTMX | Su Zhen Director |
76,000 | $0 | 76,000 (Direct) |
View |
| 2024-01-18 Option Award |
2024-01-19 8:44 pm |
N/A 2034-01-17 |
CytomX Therapeutics Inc. | CTMX | McCarthy Sean A. CEO |
770,000 | $0 | 1,317,862 (Direct) |
View |
| 2024-01-18 Option Award |
2024-01-19 8:43 pm |
N/A 2034-01-17 |
CytomX Therapeutics Inc. | CTMX | ROWLAND LLOYD A General Counsel |
200,000 | $0 | 297,996 (Direct) |
View |
| 2024-01-18 Option Award |
2024-01-19 8:41 pm |
N/A 2034-01-17 |
CytomX Therapeutics Inc. | CTMX | Ogden Christopher SVP, Finance and Accounting |
269,000 | $0 | 317,657 (Direct) |
View |
| 2024-01-18 Option Award |
2024-01-19 8:40 pm |
N/A 2034-01-17 |
CytomX Therapeutics Inc. | CTMX | Landau Jeffrey B Chief Business Officer |
245,000 | $0 | 339,302 (Direct) |
View |
| 2024-01-18 Option Award |
2024-01-19 8:38 pm |
N/A 2034-01-17 |
CytomX Therapeutics Inc. | CTMX | BELVIN MARCIA SVP, Chief Scientific Officer |
223,750 | $0 | 378,874 (Direct) |
View |
| 2024-01-18 Option Award |
2024-01-19 8:37 pm |
N/A 2034-01-17 |
CytomX Therapeutics Inc. | CTMX | Chu Yu-Waye Chief Medical Officer |
223,750 | $0 | 223,750 (Direct) |
View |